KEWAUNEE SCIENTIFIC CORP /DE/ - Quarter Report: 2005 July (Form 10-Q)
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
x | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the quarterly period ended July 31, 2005
¨ | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the transition period from to
Commission file number 0-5286
KEWAUNEE SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 38-0715562 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
2700 West Front Street Statesville, North Carolina |
28677 | |
(Address of principal executive offices) | (Zip Code) |
(704) 873-7202
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes ¨ No x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ¨ No x
As of July 5, 2005, the Registrant had outstanding 2,492,270 shares of Common Stock.
Pages: This report, excluding exhibits, contains 17 pages numbered sequentially from this cover page.
Table of Contents
KEWAUNEE SCIENTIFIC CORPORATION
INDEX TO FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED JULY 31, 2005
2
Table of Contents
Kewaunee Scientific Corporation
Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share data)
Three months ended July 31 |
||||||||
2005 |
2004 |
|||||||
Net sales |
$ | 20,308 | $ | 20,288 | ||||
Costs of products sold |
16,922 | 16,912 | ||||||
Gross profit |
3,386 | 3,376 | ||||||
Operating expenses |
2,920 | 3,046 | ||||||
Operating earnings |
466 | 330 | ||||||
Other income |
879 | 46 | ||||||
Interest expense |
(87 | ) | (86 | ) | ||||
Earnings before income taxes |
1,258 | 290 | ||||||
Income tax expense |
457 | 100 | ||||||
Earnings before minority interests |
801 | 190 | ||||||
Minority interests |
38 | (3 | ) | |||||
Net earnings |
$ | 763 | $ | 193 | ||||
Net earnings per share |
||||||||
Basic |
$ | 0.31 | $ | 0.08 | ||||
Diluted |
$ | 0.31 | $ | 0.08 | ||||
Weighted average number of common shares outstanding (in thousands) |
||||||||
Basic |
2,492 | 2,490 | ||||||
Diluted |
2,492 | 2,500 |
See accompanying notes to consolidated financial statements.
3
Table of Contents
Kewaunee Scientific Corporation
Consolidated Balance Sheets
(in thousands)
July 31 2005 |
April 30 2005 |
|||||||
(Unaudited) | ||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 646 | $ | 225 | ||||
Restricted cash |
373 | 379 | ||||||
Receivables, less allowance |
21,231 | 21,683 | ||||||
Inventories |
4,938 | 3,542 | ||||||
Deferred income taxes |
467 | 456 | ||||||
Prepaid income taxes |
| 94 | ||||||
Prepaid expenses and other current assets |
770 | 401 | ||||||
Total current assets |
28,425 | 26,780 | ||||||
Property, plant and equipment, at cost |
35,349 | 34,467 | ||||||
Accumulated depreciation |
(24,209 | ) | (23,737 | ) | ||||
Net property, plant and equipment |
11,140 | 10,730 | ||||||
Prepaid pension cost |
4,791 | 4,731 | ||||||
Property held for sale |
| 1,450 | ||||||
Other |
2,537 | 2,521 | ||||||
Total other assets |
7,328 | 8,702 | ||||||
Total Assets |
$ | 46,893 | $ | 46,212 | ||||
Liabilities and Stockholders Equity |
||||||||
Current liabilities: |
||||||||
Short-term borrowings |
$ | 5,038 | $ | 3,778 | ||||
Current portion of long-term debt |
652 | 931 | ||||||
Current obligations under capital leases |
114 | 111 | ||||||
Accounts payable |
7,443 | 8,558 | ||||||
Employee compensation and amounts withheld |
846 | 1,113 | ||||||
Deferred Revenue |
1,257 | 1,261 | ||||||
Other accrued expenses |
1,116 | 647 | ||||||
Total current liabilities |
16,466 | 16,399 | ||||||
Obligations under capital leases |
316 | 307 | ||||||
Deferred income taxes |
384 | 391 | ||||||
Accrued employee benefit plan costs |
2,517 | 2,524 | ||||||
Other long-term liabilities |
1 | 2 | ||||||
Minority interests |
634 | 600 | ||||||
Total Liabilities |
20,318 | 20,223 | ||||||
Stockholders equity: |
||||||||
Common stock |
6,550 | 6,550 | ||||||
Additional paid-in-capital |
143 | 144 | ||||||
Retained earnings |
20,619 | 20,031 | ||||||
Accumulated other comprehensive income |
50 | 54 | ||||||
Common stock in treasury, at cost |
(787 | ) | (790 | ) | ||||
Total stockholders equity |
26,575 | 25,989 | ||||||
Total Liabilities and Stockholders Equity |
$ | 46,893 | $ | 46,212 | ||||
See accompanying notes to consolidated financial statements.
4
Table of Contents
Kewaunee Scientific Corporation
Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Three months ended July 31 |
||||||||
2005 |
2004 |
|||||||
Cash flows from operating activities: | ||||||||
Net earnings |
$ | 763 | $ | 193 | ||||
Adjustments to reconcile net earnings to net cash used in operating activities: |
||||||||
Depreciation |
472 | 510 | ||||||
Provision for bad debts |
38 | 83 | ||||||
Increase in deferred income tax expense |
(18 | ) | | |||||
Gain on sale of property held for sale |
(884 | ) | | |||||
Decrease in prepaid income taxes |
94 | 165 | ||||||
Decrease (increase) in receivables |
414 | 460 | ||||||
(Increase) decrease in inventories |
(1,396 | ) | 418 | |||||
(Increase) decrease in prepaid pension cost |
(60 | ) | 211 | |||||
Increase (decrease) in accounts payable and other current liabilities |
1,388 | (1,990 | ) | |||||
(Decrease) in deferred revenue |
(4 | ) | (191 | ) | ||||
Other, net |
(529 | ) | (291 | ) | ||||
Net cash provided by (used in) operating activities |
278 | (432 | ) | |||||
Cash flows from investing activities: | ||||||||
Capital expenditures |
(832 | ) | (153 | ) | ||||
Proceeds from sale of property held for sale |
2,500 | | ||||||
Decrease (increase) in restricted cash |
6 | (3 | ) | |||||
Net cash provided by (used in) investing activities |
1,674 | (156 | ) | |||||
Cash flows from financing activities: | ||||||||
Decrease in bank overdraft |
(2,301 | ) | | |||||
Increase in short-term borrowings |
1,260 | 991 | ||||||
Payments on long-term debt |
(279 | ) | (279 | ) | ||||
Payments on capital leases |
(38 | ) | | |||||
Dividends paid |
(175 | ) | (175 | ) | ||||
Proceeds from exercise of stock options (including tax benefit) |
2 | 12 | ||||||
Net cash (used in) provided by financing activities |
(1,531 | ) | 549 | |||||
Increase (decrease) in cash and cash equivalents | 421 | (39 | ) | |||||
Cash and cash equivalents, beginning of period | 225 | 805 | ||||||
Cash and cash equivalents, end of period | $ | 646 | $ | 766 | ||||
See accompanying notes to consolidated financial statements.
5
Table of Contents
Kewaunee Scientific Corporation
Notes to Consolidated Financial Statements
(unaudited)
A. Financial Information
The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the Company or Kewaunee) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the Commission). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.
These interim consolidated financial statements should be read in conjunction with the financial statements and notes included in the Companys 2005 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
The preparation of the financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
Certain prior period amounts have been reclassified to conform to current classifications. These reclassifications had no impact on the results of operations of the Company.
B. Inventories
Inventories consisted of the following (in thousands):
July 31, 2005 |
April 30, 2005 | |||||
Finished products |
$ | 2,139 | $ | 1,054 | ||
Work in process |
902 | 929 | ||||
Raw materials |
1,897 | 1,559 | ||||
$ | 4,938 | $ | 3,542 | |||
For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim financial statements in the period in which they occur.
6
Table of Contents
C. Balance Sheet
The Companys April 30, 2005 consolidated balance sheet as presented herein is derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles.
D. Comprehensive Income
A reconciliation of net earnings and total comprehensive income for the three months ended July 31, 2005 and 2004 is as follows (in thousands):
Three months ended July 31, 2005 |
Three months ended July 31, 2004 |
|||||||
Net earnings |
$ | 763 | $ | 193 | ||||
Change in fair value of cash flow hedge, net of income tax |
1 | 4 | ||||||
Change in cumulative foreign currency translation adjustments |
(5 | ) | (18 | ) | ||||
Total comprehensive income |
$ | 759 | $ | 179 |
Statement and Financial Accounting Standards (SFAS) No. 133, Accounting for Derivative Instruments and Hedging Activities, requires that the Company record derivatives on the balance sheet at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Companys business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company may from time-to-time employ derivative financial instruments, such as interest rate swap contracts, to mitigate or eliminate certain of those risks. The Company does not enter into derivative instruments for speculative purposes. The Company had one interest rate swap agreement outstanding at July 31, 2005 that expires February 28, 2006.
For the Companys foreign subsidiaries, assets and liabilities are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders equity.
7
Table of Contents
E. Stock Options
The Company accounts for stock options using the intrinsic value method. Under this method no compensation expense is recorded since the exercise price of the stock options is equal to the market price of the underlying stock on the grant date. Had compensation expense for the stock options issued been determined consistent with Financial Accounting Standards Board (FASB) Statement No. 123R, Accounting for Stock-Based Compensation, net earnings and net earnings per share would have been reduced (increased) to the following pro forma amounts (in thousands, except per share data):
Three months ended July 31, 2005 |
Three months ended July 31, 2004 |
|||||||
Net earnings as reported |
$ | 763 | $ | 193 | ||||
Pro forma compensation cost |
(3 | ) | (8 | ) | ||||
Net earnings pro forma |
760 | 185 | ||||||
Net earnings per share Basic |
||||||||
As reported |
$ | 0.31 | $ | 0.08 | ||||
Pro forma |
0.30 | 0.07 | ||||||
Net earnings per share Diluted |
||||||||
As reported |
$ | 0.31 | $ | 0.08 | ||||
Pro forma |
0.30 | 0.07 |
F. Defined Pension Plans
The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. Effective April 30, 2005, no further benefits will be earned under the plans and no additional participants will be added to the plans. No contributions were paid to the plans during the three months ended July 31, 2005, and the Company does not expect any contributions to be paid to the plans during the remainder of the current year.
Pension expense (income) consisted of the following (in thousands):
Three months ended July 31, 2005 |
Three months ended July 31, 2004 |
|||||||
Service Cost |
$ | -0- | $ | 129 | ||||
Interest Cost |
195 | 213 | ||||||
Expected return on plan assets |
(311 | ) | (251 | ) | ||||
Amortization of prior service costs |
-0- | 3 | ||||||
Recognition of net loss |
60 | 59 | ||||||
Net periodic pension cost (income) |
$ | (56 | ) | $ | 153 |
8
Table of Contents
Item 2. Managements Discussion and Analysis
of Financial Condition and Results of Operations
The Companys 2005 Annual Report to Stockholders contains managements discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2005. The following discussion and analysis describes material changes in the Companys financial condition since April 30, 2005. The analysis of results of operations compares the three months ended July 31, 2005 with the comparable period of the prior fiscal year.
Results of Operations
Sales for the three months ended July 31, 2005 were $20,308,000, slightly above sales of $20,288,000 for the comparable period of the prior year. Domestic sales of laboratory furniture declined 6.5% during the quarter from the same period last year, while international sales of laboratory furniture increased to $1,644,000 from $585,000 in the same period last year. Sales of technical furniture were $1,365,000, as compared to $1,195,000 in the same period last year. The total order backlog was $40.7 million at July 31, 2005, as compared to $40.6 million at April 30, 2005 and $39.6 million at July 31, 2004.
The gross profit margin for the quarter ended July 31, 2005 was 16.7% of sales, as compared to 16.6% of sales in the same quarter of the prior year. The profit margin was relatively unchanged from the prior year period, as the favorable impact of activities to reduce raw material and operating costs substantially offset increases in prices of certain raw materials, most notably steel and resin.
Operating expenses for the three months ended July 31, 2005 were $2.9 million, or 14.4% of sales, as compared to $3.0 million, or 15.0% of sales, in the same period of the prior year. Operating expenses for the current year benefited from cost reduction activities, including headcount reductions in the second half of the prior year, and lower bad debt expense, which declined $45,000 from the same period last year.
Operating earnings of $466,000 were recorded for the three months ended July 31, 2005. This compares to operating earnings of $330,000 for the comparable period of the prior year.
Interest expense was $87,000 for the three months ended July 31, 2005, compared to $86,000 for the same period of the prior year. The slight increase in interest expense for the current quarter resulted from higher interest rates, which was substantially offset by lower levels of borrowings in the current year.
9
Table of Contents
Other income was $879,000, in the three months ended July 31, 2005, compared to other income of $46,000 for the comparable period of the prior year. Other income for the three months ended July 31, 2005 included $884,000 from the sale of the Companys Lockhart, Texas property.
Income tax expense of $457,000 was recorded for the three months ended July 31, 2005. This compares to income tax expense of $100,000 recorded for the three months ended July 31, 2004. The effective tax rate was approximately 36% for quarter ended July 31, 2005 and was 34% for the three months ended July 31, 2004. The effective tax rate for each of these periods differs from the statutory rate due to earned state and federal tax credits.
Minority interest related to the Companys two subsidiaries that are not 100% owned by the Company reduced net earnings by $38,000 for the three months ended July 31, 2005 and increased net earnings by $3,000 during the comparable period of the prior year.
Net earnings of $763,000, or $.31 per diluted share, were recorded for the three months ended July 31, 2005. This compares to net earnings of $193,000, or $.08 per diluted share, for the comparable period of the prior year. Net earnings for the three months ended July 31, 2005 included an after-tax gain of $540,000, or $.22 per diluted share, resulting from the sale of the Companys former plant site in Lockhart, Texas.
Liquidity and Capital Resources
Historically, the Companys principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Companys revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancelable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.
The Company had working capital of $12.0 million at July 31, 2005, as compared to $10.4 million at April 30, 2005. The ratio of current assets to current liabilities was 1.7-to-1 at July 31, 2005, as compared to 1.6-to-1 at April 30, 2005. At July 31, 2005, advances of $5,038,000 were outstanding under the Companys revolving credit loan, leaving available credit under this line in the amount of $3,962,000.
10
Table of Contents
The Companys operations provided cash of $278,000 during the three months ended July 31, 2005. Cash was provided primarily from an increase in accounts payable and other current liabilities, which was substantially offset by cash requirements resulting from an increase in inventories. The Companys operations used cash of $432,000 during the three months ended July 31, 2004. The cash was used primarily to fund a decrease in accounts payable and other current liabilities, which was partially offset by the impact of lower levels of receivables and inventories.
During the three months ended July 31, 2005, net cash of $1,674,000 was provided by investing activities, primarily from the proceeds of the sale of the Companys former plant site in Lockhart, Texas, reduced by $832,000 of capital expenditures. This compares to the use of $156,000 for investing activities in the same period of the prior year, primarily for capital expenditures.
The Companys financing activities used cash of $1,531,000 during the three months ended July 31, 2005. Cash used included $2,301,000 to reduce bank overdrafts, $279,000 for scheduled repayments of long-term debt, and $175,000 for cash dividends. The impact of these items was partially offset by cash of $1,260,000 provided from advances under the revolving credit loan. Financing activities provided cash of $549,000 in the same period of the prior year, which included $991,000 received from advances under the revolving credit loan, partially offset by scheduled long-term debt repayments of $279,000 and cash dividends paid of $175,000.
11
Table of Contents
Outlook for Remainder of Fiscal Year 2006
In addition to general economic factors affecting the Company and its markets, demand for the Companys products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Companys ability to predict future demand is very limited given, among other general economic factors affecting the Company and its markets, the Companys role as subcontractor or supplier to dealers of subcontractors.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements in this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the Reform Act). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Companys operations, markets, products, services, and prices. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by the Company prior to the effective date of the Reform Act. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms believes, belief, expects, plans, objectives, anticipates, intends or the like to be uncertain and forward-looking.
12
Table of Contents
REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS
A review of the interim financial information included in this Quarterly Report on Form 10-Q for the three months ended July 31, 2005 has been performed by Cherry, Bekaert & Holland LLP, the Companys independent auditors. Their report on the interim financial information follows.
13
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Kewaunee Scientific Corporation
Statesville, North Carolina
We have reviewed the accompanying consolidated balance sheets of Kewaunee Scientific Corporation and its subsidiaries (the Company) as of July 31, 2005, and the related consolidated statements of operations, stockholders equity and cash flows for the three-month period ended July 31, 2005. These interim financial statements are the responsibility of the companys management.
We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should be made to the consolidated interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.
Cherry, Bekaert & Holland LLP
Charlotte, North Carolina
August 24, 2005
14
Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There are no material changes to the disclosures made on this matter in the Companys Annual Report on Form 10-K for the fiscal year ended April 30, 2005.
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures
An evaluation was performed under the supervision and the participation of the companys management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of the Companys disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of July 31, 2005. Based on that evaluation, the Companys management, including the CEO and CFO, concluded that, as of July 31, 2005, the Companys disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.
(b) Changes in internal controls
There were no significant changes in the Companys internal controls or in other factors that could significantly affect these controls subsequent to July 31, 2005. As no significant deficiencies or material weaknesses were found, no corrective actions were taken.
15
Table of Contents
Item 4. Submission of Matters to a Vote of Security Holders
The Companys Annual Meeting of Stockholders was held on August 24, 2005. Each of the nominees for Class I directors was re-elected for a three-year term. The votes cast for and withheld from each such director were as follows:
Director |
For |
Withheld | ||
Wiley N. Caldwell |
2,060,502 | 122,434 | ||
Silas Keehn |
2,046,305 | 136,631 |
Item 6. Exhibits and Reports on Form 8-K
31.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
16
Table of Contents
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KEWAUNEE SCIENTIFIC CORPORATION | ||||
(Registrant) | ||||
Date: September 12, 2005 |
By | /s/ D. Michael Parker | ||
D. Michael Parker | ||||
Senior Vice President, Finance and | ||||
Chief Financial Officer |
17